Poliovirus vaccine options: another step forward
Open Access
- 9 December 2020
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 397 (10268), 2-3
- https://doi.org/10.1016/s0140-6736(20)32629-5
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trialsThe Lancet, 2020
- Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trialsThe Lancet, 2020
- Updated Characterization of Outbreak Response Strategies for 2019–2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine StrainRisk Analysis, 2020
- Updated Characterization of Post‐OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV RestartRisk Analysis, 2020
- Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccineScience, 2020
- Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio EndgameRisk Analysis, 2020
- Polio endgame options: will we have the vaccines needed?The Lancet, 2019
- The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 studyThe Lancet, 2019
- Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine‐Derived Polioviruses (cVDPVs)Risk Analysis, 2013
- Risks of Paralytic Disease Due to Wild or Vaccine‐Derived Poliovirus After EradicationRisk Analysis, 2006